CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.
EDJX is focused on creating a decentralized edge computing platform aimed at addressing the growing demand for efficient data processing. This platform offers ultra-low latency capabilities and serverless computing, enabling developers to build secure Internet of Things (IoT) and machine-to-machine (M2M) applications. By directing serverless requests to the nearest devices, EDJX minimizes latency and bandwidth constraints, allowing for seamless execution of applications in isolated environments. The company also provides essential services such as content delivery networks, object storage, and DNS, enhancing the overall functionality of its edge cloud solutions.
Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile.
CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile.
6fusion provides an end-to-end cloud management platform that enables global workload distribution by turning the public and private cloud into a pay-per-use billable utility. The unique metering algorithm, Workload Allocation Cube, creates a commercial standard to quantify supply and demand for compute resources. For IT service providers, enterprises and independent software vendors, and Infrastructure Owners/Operators, 6fusion simplifies and streamlines Infrastructure-as-a-Service via a single console that provides valuable insight into consumption, performance benchmarking and cost allocation without vendor lock-in.
LocationSmart is a leading provider of cloud-based location services headquartered in Carlsbad, California. Founded in 1995, originally as TechnoCom Corporation, the company specializes in geolocation compliance for the gaming industry, including sectors like Daily Fantasy Sports, Online Poker, and Online Casino, as well as IoT asset management. LocationSmart serves a diverse clientele ranging from startups to large multinational corporations, offering services that enhance business intelligence, customer engagement, and security. Their location-as-a-service platform can determine location through various methods, including IP address, cell or Wi-Fi ID, and mobile app SDK, while also offering messaging capabilities for geo-enabled communications. With a focus on privacy, the platform includes consent management features and geofencing capabilities, allowing businesses to create targeted campaigns while ensuring user privacy. LocationSmart's innovative solutions have earned recognition as one of the top cloud-based location service providers globally, operating across 15 billion connected devices.
CallMiner, Inc. specializes in speech analytics solutions aimed at enhancing performance in contact centers. The company offers a platform called Eureka, which utilizes artificial intelligence and natural language processing to analyze and extract insights from customer interactions, including voice conversations and written communications. Eureka provides features for automated quality monitoring, performance management, and real-time analysis of ongoing calls. CallMiner also offers products tailored for smaller contact centers, enabling automated customer service quality scoring and compliance risk assessment. In addition to its software solutions, the company provides customer support, training, and advisory services to help organizations utilize their tools effectively. CallMiner serves a diverse range of industries, including financial services, energy, manufacturing, and hospitality. Founded in 2002, the company is headquartered in Waltham, Massachusetts, with additional offices in Fort Myers, Florida, and the United Kingdom.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, specifically targeting complications such as diabetic nephropathy. Founded in 2005 and based in North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to respond to hyperglycemia. This innovative treatment aims to bind to a specific molecular target within the αVβ3 receptor, potentially offering patients a means to mitigate the serious complications associated with diabetes. Vascular Pharmaceuticals operates at the intersection of biotechnology, medicine, and healthcare, contributing to the ongoing efforts to improve outcomes for those affected by diabetes.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.
CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.
Learn to play the music you love in the Zenph Online Education Network (ZOEN). We deliver the perfect match between teachers and students through live online music lessons. Whether you’re looking to learn your favorite song, seeking advice on perfecting your technique or searching for the right music teacher for your kids, taking a live online music lesson from one of the ZOEN’s experienced, nationally renowned music teachers is just a matter of a few clicks! The ZOEN is brought to you by Zenph, Inc. – our award winning Re-Performance® technology was named one of the “Best Ideas of the Year” by The New York Times Magazine and has earned us accolades from music lovers and critics the world over, including multiple GRAMMY® nominations. Based in North Carolina’s Research Triangle Park, we are a venture-backed technology company led by a team of music and software professionals with expertise in music education, consumer software, social gaming and entertainment.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.
Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.
Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.
Zenoss Inc. specializes in developing monitoring and analytic software that provides comprehensive visibility across cloud, virtual, and physical IT environments. Its primary offering, Zenoss Cloud, is a software-as-a-service platform that aggregates and normalizes machine data, allowing organizations to anticipate and prevent service disruptions in their IT operations. The company also integrates with VxRail hyperconverged infrastructure, enabling users to monitor entire deployments effectively. Zenoss's solutions cater to various industries, including federal, financial, and technology sectors, as well as service providers, with applications in IT services, virtualization, network management, and unified communications. By employing machine learning algorithms, Zenoss helps organizations reduce downtime and optimize IT spending through real-time service models. Founded in 2005 and headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom, Zenoss maintains strategic partnerships with several prominent companies, enhancing its service offerings.
ABT Molecular Imaging is a medical imaging company that specializes in the design, manufacture, and marketing of biomarker generator systems for positron emission tomography (PET). Headquartered in Knoxville, Tennessee, the company offers the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs on demand, facilitating immediate use at the point of care. The generator incorporates features such as quality control tests and detailed dose records to ensure reliability and compliance. Founded by Ron and Lynda Nutt in 2006, ABT aims to enhance the global expansion of PET imaging by providing innovative solutions for pharmaceutical companies. Its products are distributed through a comprehensive network of sales and service partners.
Vascular Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics for patients with type 1 and type 2 diabetes, specifically targeting complications such as diabetic nephropathy. Founded in 2005 and based in North Carolina, the company is advancing its lead candidate, VPI-2690B, a subcutaneously administered monoclonal antibody designed to respond to hyperglycemia. This innovative treatment aims to bind to a specific molecular target within the αVβ3 receptor, potentially offering patients a means to mitigate the serious complications associated with diabetes. Vascular Pharmaceuticals operates at the intersection of biotechnology, medicine, and healthcare, contributing to the ongoing efforts to improve outcomes for those affected by diabetes.
Private Equity Round in 2012
Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.
Esanex
Venture Round in 2012
Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has shown outstanding pre-clinical activity in a number of tumor models and is currently completing Phase 1 trials.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.
Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.
Adaptivity is a company that specializes in optimizing IT delivery across enterprise environments. Founded in 2007 by experienced IT professionals, Adaptivity focuses on addressing the design challenges faced by enterprise IT. The company provides a range of integrated services, including cloud computing, IT forensics, datacenter transformation, and disaster recovery solutions. By leveraging real-time infrastructure and virtual datacenters, Adaptivity aims to enhance business impact through its intelligent design platform. This platform enables enterprises to optimize and redesign their systems in a dynamic and agile manner, ultimately transforming the way IT services are delivered. Adaptivity's commitment to innovation and industry partnerships has led to numerous awards, reflecting its significant contributions to the field of IT.
Semprius, Inc. is a company focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy. Based in Durham, North Carolina, Semprius utilizes a unique micro-transfer printing technology that enables the production of high-performance and reliable CPV modules at a low cost, making solar power generation economically feasible in sunny and arid climates. The company’s products are targeted for utility, commercial, industrial, and government applications and are distributed through integrators and engineering, procurement, and construction (EPC) firms. In addition to its solar applications, Semprius is licensing its micro-transfer printing technology for non-solar uses, which can facilitate the development of innovative products such as flat-panel displays, flexible electronics, and large-area sensors. Founded in 2005, Semprius continues to advance its technology to enable scalable production and broad applications in the semiconductor industry.
CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.
simplifyMD, an Alpharetta, GA-based electronic health records (EHR) provider. Founded in 2006, simplifyMD provides physician practices with a ONC-ATCB (Office of the National Coordinator-Authorized Testing and Certification Body) certified, web-based platform that offers EHR, medical-grade document management and Patient Health Record technologies.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.
Adaptivity is a company that specializes in optimizing IT delivery across enterprise environments. Founded in 2007 by experienced IT professionals, Adaptivity focuses on addressing the design challenges faced by enterprise IT. The company provides a range of integrated services, including cloud computing, IT forensics, datacenter transformation, and disaster recovery solutions. By leveraging real-time infrastructure and virtual datacenters, Adaptivity aims to enhance business impact through its intelligent design platform. This platform enables enterprises to optimize and redesign their systems in a dynamic and agile manner, ultimately transforming the way IT services are delivered. Adaptivity's commitment to innovation and industry partnerships has led to numerous awards, reflecting its significant contributions to the field of IT.
Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
6fusion provides an end-to-end cloud management platform that enables global workload distribution by turning the public and private cloud into a pay-per-use billable utility. The unique metering algorithm, Workload Allocation Cube, creates a commercial standard to quantify supply and demand for compute resources. For IT service providers, enterprises and independent software vendors, and Infrastructure Owners/Operators, 6fusion simplifies and streamlines Infrastructure-as-a-Service via a single console that provides valuable insight into consumption, performance benchmarking and cost allocation without vendor lock-in.
Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.
Semprius, Inc. is a company focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy. Based in Durham, North Carolina, Semprius utilizes a unique micro-transfer printing technology that enables the production of high-performance and reliable CPV modules at a low cost, making solar power generation economically feasible in sunny and arid climates. The company’s products are targeted for utility, commercial, industrial, and government applications and are distributed through integrators and engineering, procurement, and construction (EPC) firms. In addition to its solar applications, Semprius is licensing its micro-transfer printing technology for non-solar uses, which can facilitate the development of innovative products such as flat-panel displays, flexible electronics, and large-area sensors. Founded in 2005, Semprius continues to advance its technology to enable scalable production and broad applications in the semiconductor industry.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.
Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.
Locaid is a leading provider of Location-as-a-Service (LaaS), specializing in cloud-based geolocation and messaging services. With a global reach encompassing over 5 billion connected devices, including mobile networks with more than 360 million active connections, Locaid enables businesses to determine the physical location of customers, employees, and assets instantly. The company offers its robust, privacy-protected Omni-Location™ platform to a diverse clientele, including major carriers and Fortune 500 companies, facilitating hyper-local engagement, fraud reduction, and compliance with regulations. Locaid enhances operational efficiency by providing real-time actionable intelligence, allowing enterprises to optimize their processes and verify transactions effectively. Their services include advanced geofencing capabilities, device verification, and geo-enabled messaging solutions, all designed to improve customer engagement and security while maintaining privacy controls.
CallMiner, Inc. specializes in speech analytics solutions aimed at enhancing performance in contact centers. The company offers a platform called Eureka, which utilizes artificial intelligence and natural language processing to analyze and extract insights from customer interactions, including voice conversations and written communications. Eureka provides features for automated quality monitoring, performance management, and real-time analysis of ongoing calls. CallMiner also offers products tailored for smaller contact centers, enabling automated customer service quality scoring and compliance risk assessment. In addition to its software solutions, the company provides customer support, training, and advisory services to help organizations utilize their tools effectively. CallMiner serves a diverse range of industries, including financial services, energy, manufacturing, and hospitality. Founded in 2002, the company is headquartered in Waltham, Massachusetts, with additional offices in Fort Myers, Florida, and the United Kingdom.
Adaptivity is a company that specializes in optimizing IT delivery across enterprise environments. Founded in 2007 by experienced IT professionals, Adaptivity focuses on addressing the design challenges faced by enterprise IT. The company provides a range of integrated services, including cloud computing, IT forensics, datacenter transformation, and disaster recovery solutions. By leveraging real-time infrastructure and virtual datacenters, Adaptivity aims to enhance business impact through its intelligent design platform. This platform enables enterprises to optimize and redesign their systems in a dynamic and agile manner, ultimately transforming the way IT services are delivered. Adaptivity's commitment to innovation and industry partnerships has led to numerous awards, reflecting its significant contributions to the field of IT.
CallMiner, Inc. specializes in speech analytics solutions aimed at enhancing performance in contact centers. The company offers a platform called Eureka, which utilizes artificial intelligence and natural language processing to analyze and extract insights from customer interactions, including voice conversations and written communications. Eureka provides features for automated quality monitoring, performance management, and real-time analysis of ongoing calls. CallMiner also offers products tailored for smaller contact centers, enabling automated customer service quality scoring and compliance risk assessment. In addition to its software solutions, the company provides customer support, training, and advisory services to help organizations utilize their tools effectively. CallMiner serves a diverse range of industries, including financial services, energy, manufacturing, and hospitality. Founded in 2002, the company is headquartered in Waltham, Massachusetts, with additional offices in Fort Myers, Florida, and the United Kingdom.
6fusion provides an end-to-end cloud management platform that enables global workload distribution by turning the public and private cloud into a pay-per-use billable utility. The unique metering algorithm, Workload Allocation Cube, creates a commercial standard to quantify supply and demand for compute resources. For IT service providers, enterprises and independent software vendors, and Infrastructure Owners/Operators, 6fusion simplifies and streamlines Infrastructure-as-a-Service via a single console that provides valuable insight into consumption, performance benchmarking and cost allocation without vendor lock-in.
Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Overture Networks develops and manufactures high-speed carrier ethernet edge and aggregation solutions. Its products combine packet-switched and circuit-switched areas into a single architecture-at cost points to offer carrier Ethernet services to any size location over copper, fiber, or optical transport.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.
ABT Molecular Imaging is a medical imaging company that specializes in the design, manufacture, and marketing of biomarker generator systems for positron emission tomography (PET). Headquartered in Knoxville, Tennessee, the company offers the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs on demand, facilitating immediate use at the point of care. The generator incorporates features such as quality control tests and detailed dose records to ensure reliability and compliance. Founded by Ron and Lynda Nutt in 2006, ABT aims to enhance the global expansion of PET imaging by providing innovative solutions for pharmaceutical companies. Its products are distributed through a comprehensive network of sales and service partners.
Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. Our proprietary microchip-based implant can store and release precise doses of drugs over months and years. The implant, which is placed under the skin by a trained physician during a simple office procedure using local anesthesia, can be wirelessly activated or deactivated by a physician or patient, without requiring removal. In addition, physicians can wirelessly modify the frequency or dose of the drug to meet the individual needs of each patient.
PeopleMatter, Inc. is a workforce management platform that specializes in talent management software tools aimed at enhancing the performance of service-industry brands. Founded in 2001 and based in Charleston, South Carolina, the company develops solutions tailored for various sectors, including technology, transportation, healthcare, government, biotech, and recreation. The platform focuses on improving the hiring process for hourly workers by simplifying sourcing, screening, and onboarding, thereby increasing efficiency and engagement for both employers and employees. PeopleMatter was acquired by Snagajob in June 2016, positioning it to further enhance its offerings in the realm of hourly workforce management.
Calibra Medical
Venture Round in 2009
Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.
Zenph Sound Innovations
Series A in 2009
Acquired by Steinway & Sons Inc., January 2015. Zenph Sound Innovations is a developer of musical analysis technology focused on software services and apps related to music. Zenph Sound Innovations offers technology that converts audio recordings into datasets, enabling a virtual artist play re-performances, precisely replicating a musician’s playing in an original recording.
Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. The firm aims to improve the surgical experience for both surgeons and patients by integrating advanced technologies such as augmented intelligence, connectivity, and robotics into the surgical process. Its flagship product, the Senhance Surgical System, represents the first machine vision system designed for robotic surgery, enhanced by the Intelligent Surgical Unit that facilitates augmented intelligence. By addressing existing clinical, cognitive, and economic challenges within the surgical field, Asensus Surgical seeks to transform surgical practices and improve outcomes for patients globally.
Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Semprius, Inc. is a company focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy. Based in Durham, North Carolina, Semprius utilizes a unique micro-transfer printing technology that enables the production of high-performance and reliable CPV modules at a low cost, making solar power generation economically feasible in sunny and arid climates. The company’s products are targeted for utility, commercial, industrial, and government applications and are distributed through integrators and engineering, procurement, and construction (EPC) firms. In addition to its solar applications, Semprius is licensing its micro-transfer printing technology for non-solar uses, which can facilitate the development of innovative products such as flat-panel displays, flexible electronics, and large-area sensors. Founded in 2005, Semprius continues to advance its technology to enable scalable production and broad applications in the semiconductor industry.
Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.
Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.
Bright View Technologies, Inc. is a leading developer of microstructure-based, optical films for the global display industry. They are leveraging patented and proprietary technologies that enable the production of unique optical film products with superior performance characteristics for Plasma, LCD, Rear Projection, Front Projection and OLED.
Ziptronix, Inc. designs, develops, and markets semiconductor integration technologies to the electronics industry. The company offers chip stacking, three dimensional integrated circuits, and silicon substrate applications.
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.
Clarabridge is a customer experience management platform that assists businesses in enhancing their customer interactions. By employing advanced text analytics and natural language processing, Clarabridge transforms various forms of customer feedback, including contact center calls, comments, and reviews, into actionable insights. This empowers organizations to make informed decisions that improve customer satisfaction and drive sales growth. With a focus on providing comprehensive engagement solutions, Clarabridge has supported numerous leading brands in understanding and refining their customer experience strategies.
Calibra Medical
Series B in 2008
Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.
Athenix is a prominent player in the field of agricultural and industrial biotechnology, specializing in the development of products, technologies, and processes tailored for agricultural and chemical applications. The company is dedicated to discovering new genes and transforming them into practical solutions that address specific customer requirements. Athenix focuses on creating plants, microbes, enzymes, and processes aimed at enhancing insect and nematode resistance, as well as herbicide tolerance. Additionally, its research extends to the identification of genes and proteins utilized in the chemical and animal feed industries, reinforcing its commitment to innovation in biotechnology.
siXis is a semiconductor company that provides silicon circuit board technology.
Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.
Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.
Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.
Ziptronix, Inc. designs, develops, and markets semiconductor integration technologies to the electronics industry. The company offers chip stacking, three dimensional integrated circuits, and silicon substrate applications.
Mixx is a social news platform that allows users to discover and share news based on their interests and location. Founded by Chris McGill, former General Manager of Yahoo News, Mixx combines elements of social networking with news aggregation, creating a personalized experience for each user. Users can bookmark stories, photos, and videos, as well as submit and vote on content, fostering a community-driven environment. The platform also provides a customized homepage featuring relevant news items, popular stories, and categorized sections such as business, sports, and health. Additionally, users can join topical groups to refine the news they receive. Mixx aims to support niche publishers by promoting less mainstream topics that may not gain traction on larger platforms. By partnering with publishing entities, Mixx facilitates traffic exchange, benefiting both users and content creators.
Zenoss Inc. specializes in developing monitoring and analytic software that provides comprehensive visibility across cloud, virtual, and physical IT environments. Its primary offering, Zenoss Cloud, is a software-as-a-service platform that aggregates and normalizes machine data, allowing organizations to anticipate and prevent service disruptions in their IT operations. The company also integrates with VxRail hyperconverged infrastructure, enabling users to monitor entire deployments effectively. Zenoss's solutions cater to various industries, including federal, financial, and technology sectors, as well as service providers, with applications in IT services, virtualization, network management, and unified communications. By employing machine learning algorithms, Zenoss helps organizations reduce downtime and optimize IT spending through real-time service models. Founded in 2005 and headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom, Zenoss maintains strategic partnerships with several prominent companies, enhancing its service offerings.
NovaMin Technology provides a range of oral hygiene solutions. The company was founded by Randy Scott in 2004 and is based in Alachua, Florida.
nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.
Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.
Overture Networks develops and manufactures high-speed carrier ethernet edge and aggregation solutions. Its products combine packet-switched and circuit-switched areas into a single architecture-at cost points to offer carrier Ethernet services to any size location over copper, fiber, or optical transport.
Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.
Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.
Semprius, Inc. is a company focused on the design, development, and manufacture of high concentration photovoltaic (HCPV) solar modules aimed at generating solar energy. Based in Durham, North Carolina, Semprius utilizes a unique micro-transfer printing technology that enables the production of high-performance and reliable CPV modules at a low cost, making solar power generation economically feasible in sunny and arid climates. The company’s products are targeted for utility, commercial, industrial, and government applications and are distributed through integrators and engineering, procurement, and construction (EPC) firms. In addition to its solar applications, Semprius is licensing its micro-transfer printing technology for non-solar uses, which can facilitate the development of innovative products such as flat-panel displays, flexible electronics, and large-area sensors. Founded in 2005, Semprius continues to advance its technology to enable scalable production and broad applications in the semiconductor industry.
Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.
Serenex is a U.S.-based medical drug discovery and development company that specializes in oncology and related therapeutic areas. Founded in 2000 and acquired by Pfizer in 2008, Serenex has developed a proprietary Hsp90 product platform that includes a range of small molecule Hsp90 inhibitors targeting cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative conditions such as Alzheimer's. Additionally, the company is advancing SNX-1012, a treatment aimed at alleviating oral mucositis in patients with solid tumors. Through its innovative approach to drug development, Serenex aims to address significant unmet medical needs in various disease areas.
Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.
Mixx is a social news platform that allows users to discover and share news based on their interests and location. Founded by Chris McGill, former General Manager of Yahoo News, Mixx combines elements of social networking with news aggregation, creating a personalized experience for each user. Users can bookmark stories, photos, and videos, as well as submit and vote on content, fostering a community-driven environment. The platform also provides a customized homepage featuring relevant news items, popular stories, and categorized sections such as business, sports, and health. Additionally, users can join topical groups to refine the news they receive. Mixx aims to support niche publishers by promoting less mainstream topics that may not gain traction on larger platforms. By partnering with publishing entities, Mixx facilitates traffic exchange, benefiting both users and content creators.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.
FlatBurger, Inc. provides business infrastructure for supporting software developers working in hybrid software environments. It offers business infrastructure to complement the development tools employed in the Microsoft visual studio environment. The company focuses on serving the DotNetNuke community of software developers. FlatBurger, Inc. is based in Loudonville, New York with additional offices in northern Virginia and Troy.
Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.
6th Sense Analytics provides software solutions for automated collection and analysis of software engineering process and product data. The company was founded in 2004 and is based in Morrisville, North Carolina. As of January 12, 2009, 6th Sense Analytics operates as a subsidiary of Rally Software Development Corp.
Clarabridge is a customer experience management platform that assists businesses in enhancing their customer interactions. By employing advanced text analytics and natural language processing, Clarabridge transforms various forms of customer feedback, including contact center calls, comments, and reviews, into actionable insights. This empowers organizations to make informed decisions that improve customer satisfaction and drive sales growth. With a focus on providing comprehensive engagement solutions, Clarabridge has supported numerous leading brands in understanding and refining their customer experience strategies.
Ziptronix, Inc. designs, develops, and markets semiconductor integration technologies to the electronics industry. The company offers chip stacking, three dimensional integrated circuits, and silicon substrate applications.
Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.
Jacket Micro Devices specializes in providing solutions for wireless modules, focusing on technology that minimizes the size and cost of radio frequency components in wireless devices. Founded in 2004 and located in Atlanta, Georgia, the company offers a range of products including modules, design services, and substrates for integrated wireless systems. Additionally, it develops advanced technologies such as multi-layer organic (MLO) and low temperature laminated organic (LTLO) for system-in-package (SiP) designs, enhancing the efficiency and performance of wireless communications.
nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.
Zenoss Inc. specializes in developing monitoring and analytic software that provides comprehensive visibility across cloud, virtual, and physical IT environments. Its primary offering, Zenoss Cloud, is a software-as-a-service platform that aggregates and normalizes machine data, allowing organizations to anticipate and prevent service disruptions in their IT operations. The company also integrates with VxRail hyperconverged infrastructure, enabling users to monitor entire deployments effectively. Zenoss's solutions cater to various industries, including federal, financial, and technology sectors, as well as service providers, with applications in IT services, virtualization, network management, and unified communications. By employing machine learning algorithms, Zenoss helps organizations reduce downtime and optimize IT spending through real-time service models. Founded in 2005 and headquartered in Austin, Texas, with an additional office in Coventry, United Kingdom, Zenoss maintains strategic partnerships with several prominent companies, enhancing its service offerings.
Covega Corporation specializes in the development of optoelectronic components and subsystems, utilizing proprietary technologies in Indium Phosphide (InP) and Lithium Niobate (LiNbO3) to produce high-performance optical devices and modules. The company offers a range of products, including superluminescent diodes, semiconductor optical amplifiers, Fabry Perot lasers, gain chips, broad area lasers, and various types of modulators. Initially focused on the telecommunications, datacom, and CATV sectors, Covega has diversified its revenue streams and now derives over one-third of its income from the defense, medical, industrial, and instrumentation markets. By providing vertically integrated capabilities and foundry services, Covega meets the diverse needs of its clients across multiple industries with innovative and cost-effective solutions.